4baseCare, a precision oncology company building population-relevant clinico-genomic intelligence, has collaborated with France-based Owkin, an agentic AI company focused on Biological Artificial Superintelligence (BASI), to advance inclusive cancer research.
Through this collaboration, the two companies will work together to convert fragmented cancer care data into AI-ready intelligence. The goal is to bridge the data gap and long-standing underrepresentation of Asian and Middle Eastern populations in cancer care and drug development. By building more representative datasets, the partnership aims to support more inclusive research and create more equitable standards of cancer care worldwide.
4baseCare is a precision oncology company that is bridging the genomics data gap in cancer care. 4baseCare’s TarGT™ Indiegene test provides deeper insight into a patient’s disease, enabling targeted treatment decisions instead of a one-size-fits-all approach.
Owkin is an Agentic AI company building Biological Artificial Intelligence to transform drug discovery and development. It created the first Agent for Biology, K Pro, designed to connect research to care. Founded on the belief that precision health depends on AI powered by high-quality patient data, Owkin unlocks insights from fragmented biomedical datasets across hospitals and research centers. K Pro analyzes and structures this multimodal data into AI-ready assets, generating actionable insights that guide smarter biopharma decisions. By continuously integrating real-world patient data, K Pro drives biological discovery, de-risks and accelerates clinical trials, and advances diagnostics, directly helping bring better treatments to patients faster.
Thomas Clozel, CEO and Co-Founder, Owkin, said, “We are on a mission to build biological artificial superintelligence to cure all diseases. Global patient data is the key to unlocking this. We are excited to enhance our collaborations in India to turn fragmented datasets into meaningful discoveries for more inclusive therapeutic breakthroughs” Kshitij Rishi, COO & Co-Founder, 4baseCare, said, “Precision oncology is only as strong as the data behind it. At 4baseCare, we build inclusive genomic datasets reflecting the diversity of the global south, non Caucasian patients and combine them with advanced AI to enable more informed treatment decisions. We look forward to working with Owkin to ensure underrepresented populations are meaningfully included in global research and next-generation drug development.”